THE global leader in  blood management solutions for our customers

RSS Content

Haemonetics 2nd Quarter and 1st Half Fiscal 2018 Earnings Release Available on Investor Relations Website
Financial release accessible online

BRAINTREE, Mass., Nov. 7, 2017 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that second quarter and first half fiscal 2018 financial results are available on its Investor relations website.

HAE logo April 2016.

The Company is posting this press release and, additionally, results tables that will be referenced on its webcast to its Investor Relations website. 

Direct link to Earnings Release 2Q and 1H FY18:

http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9Mzg5NzAwfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636427304704243624

Direct link to Results Tables 2Q and 1H FY18 That Will Be Referenced on Webcast:

http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzkxMjk4fENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636438486074607995

As previously announced, the Company will host a conference call with investors and analysts to discuss and answer questions about the results at 8:00am Eastern Time on November 7, 2017. A live webcast of the call can be accessed on Haemonetics' investor relations website.

Direct link to Conference Call Webcast: https://edge.media-server.com/m6/p/cuu23zsw.

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for our customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.         

CONTACT:
Gerry Gould, VP-Investor Relations
(781) 356-9402
gerry.gould@haemonetics.com

View original content with multimedia:http://www.prnewswire.com/news-releases/haemonetics-2nd-quarter-and-1st-half-fiscal-2018-earnings-release-available-on-investor-relations-website-300550189.html

SOURCE Haemonetics Corporation